Immunogenicity of a single dose of BNT162b2, ChAdOx1 nCoV-19, or CoronaVac against SARS-CoV-2 delta and omicron variants among previously infected adults: A randomized trial.

Suvimol Niyomnaitham Zheng Quan Toh Paul Vincent Licciardi Patimaporn Wongprompitak Kanjana Srisutthisamphan Katherine Kradangna Copeland Kulkanya Chokephaibulkit

J Infect

Siriraj Institute of Clinical Research (SICRES), Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand; Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700 Thailand. Electronic address:

Published: October 2022

Download full-text PDF	Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212727	PMC
http://dx.doi.org/10.1016/j.jinf.2022.06.014	DOI Listing

Publication Analysis

Top Keywords

immunogenicity single

single dose

dose bnt162b2

bnt162b2 chadox1

chadox1 ncov-19

ncov-19 coronavac

coronavac sars-cov-2

sars-cov-2 delta

delta omicron

omicron variants

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!